OBJECTIVE： To observe therapeutic efficacy and safety of Shensong yangxin capsules combined with edaravone in the treatment of cerebrovascular disease complicated with cerebrocardiac syndrome （CCS）. METHODS： A total of 128 cerebrovascular disease patients with CCS were randomly divided into control group （64 cases） and observation group （64 cases）. Control group received routine treatment， observation group was additionally given Shensong yangxin capsule 1.6 g orally， 3 times a day+Edaravone injection 30 mg added into 0.9％ Sodium chloride solution 250 mL intravenously， 2 times a day. Treatment courses of 2 groups lasted for 10 d. Clinical efficacies of 2 groups were observed， and MDA， SOD， catecholamine （NE， E， DA） levels， cTnI， NIHSS scores， correlation of cTnI level with NIHSS score were also observed before and after treatment. The occurrence of ADR was recorded. RESULTS： Total response rate of nervous system and electrocardio gram in observation group were significantly higher than control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in MDA， SOD， NE， E， DA， cTnI levels or NIHSS scores between 2 groups （P＞0.05）. After treatment， MDA， NE， E， DA， cTnI levels and NIHSS scores of 2 groups were significantly lower than before， and the observation group was significantly lower than the control group； SOD of 2 groups were significantly higher than before，and the observation group was significantly higher than the antrol group，with statistical significance （P＜0.05）. cTnI level was positively correlated with NIHSS score （r＝0.956，P＝0.001）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Shensong yangxin capsules combined with edaravone can significantly improve therapeutic efficacy of cerebrovascular disease patients with CCS， and improve the levels of catecholamine， MDA and SOD without increasing the occurrence of ADR.